Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glibenclamide (5mg) + Metformin (500mg) Tablet
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Glibclay M 500 Tablet combines Glibenclamide 5mg and Metformin 500mg, providing a balanced dual-action approach for managing type-2 diabetes mellitus. It is prescribed for patients who require combination therapy to achieve optimal glycemic control.
Glibenclamide stimulates pancreatic insulin secretion, while Metformin enhances insulin sensitivity and reduces hepatic glucose output. Together, they offer effective control over fasting and postprandial blood sugar levels.
This combination is ideal for patients who do not achieve target glucose levels with monotherapy and ensures long-term metabolic stability. Its oral administration and favorable tolerability profile support adherence and consistent therapy outcomes.
Adding Glibclay M 500 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings in chronic care management, unlocking opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.
Some patients may experience nausea, vomiting, abdominal discomfort, diarrhea, dizziness, or headache. Hypoglycemia may occur due to Glibenclamide. Rarely, lactic acidosis or allergic reactions may occur.
Glibclay M 500 Tablet is indicated for the management of type 2 diabetes mellitus in patients who require dual therapy for effective glycemic control when diet and exercise alone are insufficient.
Use strictly under medical supervision. Monitor blood glucose regularly to avoid hypoglycemia. Avoid use in patients with severe renal or hepatic impairment. Follow the prescribed dosage and lifestyle recommendations carefully.
Store in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.
Composition : Calcium Dobesilate Monohydrate I.P. 500 mg Capsule
Composition : L-Arginine (3gm) + Proanthocyanidin (75mg) sachet
Composition : Aminacrine HCl 0.1g + Cetrimide Cream 0.5g
Composition : Chlorhexidine Gluconate (0.20% w/w) + Silver Nitrate (0.20% w/w) cream
Composition : Hydroquinone (2% w/w) + Mometasone (0.1% w/w) + Tretinoin (0.025% w/w)
Composition : Fusidic Acid I.P. 2.00% w/w + Beclomethasone Dipropionate I.P. 0.025% w/w
Composition : Cranberry Extract 300mg + D-Mannose 600mg Tablet
Composition : Terbinafine (1% w/w)
Composition : Tretinoin 0.05% Cream
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This combination has strong demand in the anti-diabetic and chronic disease management segment, making it a high-utility product for medical distributors, wholesalers, and pharma franchise partners focusing on diabetes care portfolios.
Medical distributors and agencies can benefit from consistent demand for management of Type 2 Diabetes Mellitus, insulin resistance, and long-term blood sugar control. Glibenclamide 5mg stimulates insulin release from the pancreas Metformin 500mg reduces glucose production and improves insulin sensitivity This dual mechanism strengthens effective glycemic control and builds a strong diabetes-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Glibenclamide + Metformin Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong physician prescriptions, high diabetic patient base, long-term recurring sales, stable market demand, reliable supply chain support, and good margins in anti-diabetic medicines.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.